GSK Backed By Fed. Circ. In Leukemia Drug Patent Suit
The Federal Circuit on Tuesday determined that GlaxoSmithKline LLC's leukemia drug Arzerra doesn't infringe a Biogen Idec Inc. and Genentech Inc. patent covering an antibody therapy....To view the full article, register now.
Already a subscriber? Click here to view full article